Cytosorbents (CTSO) Net Income towards Common Stockholders Growth (3y) (2013 - 2026)
Cytosorbents (CTSO) Net Income towards Common Stockholders Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn | -6.51% |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn | 7.96% |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn | 1.93% |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn | 64.73% |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn | - |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn | 60.12% |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn | 29.56% |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - | - |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn | 31.01% |
| 10 | Cytosorbents | 23.04 Mn | 18.24 Mn | 6.13 Mn | 11.20% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 11.20% |
| Dec 31, 2025 | -92.87% |
| Sep 30, 2025 | 36.19% |
| Jun 30, 2025 | 29.64% |
| Mar 31, 2025 | 45.16% |
| Dec 31, 2024 | 6.67% |
| Sep 30, 2024 | 24.40% |
| Jun 30, 2024 | 2.81% |
| Mar 31, 2024 | -15.12% |
| Dec 31, 2023 | -104.96% |
| Sep 30, 2023 | -122.05% |
| Jun 30, 2023 | -28.99% |
| Mar 31, 2023 | -28.50% |
| Dec 31, 2022 | 42.11% |
| Sep 30, 2022 | -21.01% |
| Jun 30, 2022 | -45.29% |
| Mar 31, 2022 | -22.45% |
| Dec 31, 2021 | -19.87% |
| Sep 30, 2021 | -28.71% |
| Jun 30, 2021 | 7.03% |